Allogene Therapeutics, Inc.
US ˙ NasdaqGS ˙ US0197701065

SecurityALLO / Allogene Therapeutics, Inc.
InstitutionCitigroup Inc
Latest Disclosed Ownership353,335 shares
Latest Disclosed Value $ 862,137
Citigroup Inc ownership in ALLO / Allogene Therapeutics, Inc.

On May 11, 2026 - Citigroup Inc filed a 13F-HR form disclosing ownership of 353,335 shares of Allogene Therapeutics, Inc. (US:ALLO) valued at $862,137 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 591,952 shares of Allogene Therapeutics, Inc.. This represents a change in shares of -40.31% during the quarter. The current value of the position is $706,670 USD.

Citigroup Inc has a history of taking positions in derivatives of the underlying security (ALLO) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

ALLO / Allogene Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 353,335 -238,617 -40.31 862 6.42 0.0002
2026-02-13 2025-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 591,952 -2,147 -0.36 811 10.05 0.0004
2025-11-10 2025-09-30 13F ALLOGENE THERAPEUTICS COM 019770106 594,099 -48,443 -7.54 737 1.38 0.0003
2025-08-11 2025-06-30 13F ALLOGENE THERAPEUTICS COM 019770106 642,542 -45,982 -6.68 726 -27.76 0.0004
2025-05-12 2025-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 688,524 -27,712 -3.87 1,005 -34.10 0.0005
2025-02-12 2024-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 716,236 246,926 52.61 1,526 16.06 0.0009
2024-11-12 2024-09-30 13F ALLOGENE THERAPEUTICS COM 019770106 469,310 394,138 524.31 1,314 650.86 0.0008
2024-08-12 2024-06-30 13F ALLOGENE THERAPEUTICS COM 019770106 75,172 -603,057 -88.92 175 -94.23 0.0001
2024-05-10 2024-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 678,229 643,905 1,875.96 3,032 2,655.45 0.0020
2024-02-09 2023-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 34,324 -304,432 -89.87 110 -89.75 0.0001
2023-12-06 2023-09-30 13F/A-1 ALLOGENE THERAPEUTICS COM 019770106 338,756 57,392 20.40 1,074 -23.25 0.0008
2023-11-09 2023-09-30 13F ALLOGENE THERAPEUTICS COM 019770106 338,756 57,392 1,074 0.0003
2023-08-10 2023-06-30 13F ALLOGENE THERAPEUTICS COM 019770106 281,364 -273,979 -49.34 1,398 -49.03 0.0009
2023-05-11 2023-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 555,343 210,972 61.26 2,743 26.64 0.0019
2023-02-09 2022-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 344,371 -113,418 -24.78 2,166 -56.19 0.0017
2022-11-10 2022-09-30 13F ALLOGENE THERAPEUTICS COM 019770106 457,789 216,824 89.98 4,944 79.98 0.0035
2022-08-10 2022-06-30 13F ALLOGENE THERAPEUTICS COM 019770106 240,965 121,800 102.21 2,747 152.95 0.0020
2022-05-12 2022-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 119,165 -146,219 -55.10 1,086 -72.57 0.0007
2022-02-10 2021-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 265,384 138,729 109.53 3,959 21.63 0.0021
2021-11-10 2021-09-30 13F ALLOGENE THERAPEUTICS COM 019770106 126,655 -71,633 -36.13 3,255 -37.05 0.0019
2021-08-10 2021-06-30 13F ALLOGENE THERAPEUTICS COM 019770106 198,288 74,327 59.96 5,171 18.17 0.0031
2021-05-13 2021-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 123,961 101,390 449.20 4,376 667.72 0.0028
2021-02-11 2020-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 22,571 11,806 109.67 570 40.39 0.0003
2020-11-12 2020-09-30 13F ALLOGENE THERAPEUTICS COM 019770106 10,765 -39,105 -78.41 406 -80.99 0.0003
2020-08-12 2020-06-30 13F ALLOGENE THERAPEUTICS COM 019770106 49,870 4,254 9.33 2,136 140.81 0.0017
2020-05-12 2020-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 45,616 504 1.12 887 -24.32 0.0008
2020-02-12 2019-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 45,112 2,733 6.45 1,172 1.47 0.0008
2019-11-08 2019-09-30 13F ALLOGENE THERAPEUTICS COM 019770106 42,379 -50,790 -54.51 1,155 -53.84 0.0009
2019-08-12 2019-06-30 13F ALLOGENE THERAPEUTICS COM 019770106 93,169 89,284 2,298.17 2,502 2,133.93 0.0020
2019-05-13 2019-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 3,885 -1,747 -31.02 112 -26.32 0.0001
2019-02-12 2018-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 5,632 5,632 152 0.0002
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2023-02-09 2022-12-31 13F ALLOGENE THERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2022-11-10 2022-09-30 13F ALLOGENE THERAPEUTICS COM Call 30,000 324 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2023-02-09 2022-12-31 13F ALLOGENE THERAPEUTICS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2022-11-10 2022-09-30 13F ALLOGENE THERAPEUTICS COM Put 30,000 324 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.